0QCO.LSE Pharming Group N.V.

Healthcare Biotechnology London Exchange
0.7852 EUR
Close of Nov 3, 2026
0.8196 1.83
Market cap
EUR 501M
P/E
53.6x
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.

Is 0QCO.LSE undervalued?

Graham number

The Graham number of Pharming Group N.V. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Pharming Group N.V. fundamental analysis

No fundamental analysis for Pharming Group N.V. yet.

Pharming Group N.V. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Pharming Group N.V.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treat…

Full company profile